The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Cancer Target: Mesothelin

thomas.m
thomas.m CSN Member Posts: 2 Member
edited January 2023 in Gynecological Cancers (other than ovarian and uterine) #1

Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein. Its biological function has not yet been clarified, but due to its limited distribution in normal tissues and high expression in some tumor tissues, it is expected to be used in tumor-specific treatment.

In existing studies of human epidermoid carcinoma cell lines expressing mesothelin, biodistribution analysis of mesothelin using radiolabeled monoclonal antibodies showed good localization and specificity for relevant tumors. So far, anti-mesothelin antibody-drug conjugates have been successfully used to treat mesothelin-expressing solid tumors, including ovarian cancer, pancreatic cancer, and malignant mesothelioma; and mesothelin targets chimeric antigen receptor (CAR) T cell therapy also showed significant antitumor effects. Therefore, targeted therapy and immunotherapy against mesothelin show promising application prospects.

Like Care

Discussion Boards